|Other Names||Receptor-type tyrosine-protein kinase FLT3, FL cytokine receptor, Fetal liver kinase-2, FLK-2, Fms-like tyrosine kinase 3, FLT-3, Stem cell tyrosine kinase 1, STK-1, CD135, FLT3, CD135, FLK2, STK1|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Synonyms||CD135, FLK2, STK1|
|Function||Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.|
|Cellular Location||Membrane; Single-pass type I membrane protein. Endoplasmic reticulum lumen. Note=Constitutively activated mutant forms with internal tandem duplications are less efficiently transported to the cell surface and a significant proportion is retained in an immature form in the endoplasmic reticulum lumen. The activated kinase is rapidly targeted for degradation|
|Tissue Location||Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a class III receptor tyrosine kinasethat regulates hematopoiesis. The receptor consists of anextracellular domain composed of five immunoglobulin-like domains,one transmembrane region, and a cytoplasmic kinase domain splitinto two parts by a kinase-insert domain. The receptor is activatedby binding of the fms-related tyrosine kinase 3 ligand to theextracellular domain, which induces homodimer formation in theplasma membrane leading to autophosphorylation of the receptor. Theactivated receptor kinase subsequently phosphorylates and activatesmultiple cytoplasmic effector molecules in pathways involved inapoptosis, proliferation, and differentiation of hematopoieticcells in bone marrow. Mutations that result in the constitutiveactivation of this receptor result in acute myeloid leukemia andacute lymphoblastic leukemia.
Haslam, K., et al. Ir J Med Sci 179(4):507-510(2010)Wang, E.S., et al. Cancer Genet. Cytogenet. 202(2):101-107(2010)Metzelder, S.K., et al. Dtsch. Med. Wochenschr. 135(38):1852-1856(2010)McCormick, S.R., et al. Arch. Pathol. Lab. Med. 134(8):1143-1151(2010)Rocquain, J., et al. BMC Cancer 10, 401 (2010) :
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.